ALX ONCOLOGY HOLDINGS INC Short-term Lease, Cost
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Short-term Lease, Cost of $30.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ShortTermLeaseCost · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC short-term lease, cost for the quarter ending 2026-06-30 was $30.00K.
- ALX ONCOLOGY HOLDINGS INC short-term lease, cost for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC short-term lease, cost for the quarter ending 2024-09-30 was $3.00K, a 50.00% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC short-term lease, cost for the quarter ending 2024-06-30 was $3.00K, a 0.00% change year-over-year.
- ALX ONCOLOGY HOLDINGS INC short-term lease, cost for fiscal 2024 was $14.00K, a 17.65% decline from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC short-term lease, cost for fiscal 2023 was $17.00K, a 80.68% decline from fiscal 2022.
- ALX ONCOLOGY HOLDINGS INC short-term lease, cost for fiscal 2022 was $88.00K.
| Period end | Short-term Lease, Cost 3 month | Short-term Lease, Cost 6 month | Short-term Lease, Cost 9 month | Short-term Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.00K 10-Q · filed 2026-08-06 | $30.00K 10-Q · filed 2026-08-06 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $3.00K derived: sum of 2 quarters · filed 2026-03-09 | $6.00K derived: sum of 3 quarters · filed 2026-03-09 | $14.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $3.00K 10-Q · filed 2025-11-07 | $6.00K derived: sum of 2 quarters · filed 2025-11-07 | $14.00K 10-Q · filed 2025-11-07 | $23.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $3.00K 10-Q · filed 2025-08-12 | $11.00K 10-Q · filed 2025-08-12 | $20.00K derived: sum of 3 quarters · filed 2026-03-09 | $22.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | $8.00K 10-Q · filed 2025-05-08 | $17.00K derived: sum of 2 quarters · filed 2026-03-09 | $19.00K derived: sum of 3 quarters · filed 2026-03-09 | $22.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $11.00K derived: sum of 2 quarters · filed 2026-03-09 | $14.00K derived: sum of 3 quarters · filed 2026-03-09 | $17.00K 10-K · filed 2026-03-09 |
| 2023-09-30 | $2.00K 10-Q · filed 2024-11-07 | $5.00K derived: sum of 2 quarters · filed 2024-11-07 | $8.00K 10-Q · filed 2024-11-07 | $10.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $3.00K 10-Q · filed 2023-08-10 | $6.00K 10-Q · filed 2024-08-12 | $8.00K derived: sum of 3 quarters · filed 2025-03-06 | $11.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $3.00K 10-Q · filed 2024-08-12 | $5.00K derived: sum of 2 quarters · filed 2025-03-06 | $8.00K derived: sum of 3 quarters · filed 2025-03-06 | $47.00K derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $5.00K derived: sum of 2 quarters · filed 2025-03-06 | $44.00K derived: sum of 3 quarters · filed 2025-03-06 | $88.00K 10-K · filed 2025-03-06 |
| 2022-09-30 | $3.00K 10-Q · filed 2023-11-13 | $42.00K derived: sum of 2 quarters · filed 2023-11-13 | $86.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $39.00K 10-Q · filed 2023-08-10 | $83.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $44.00K 10-Q · filed 2023-05-11 | |||
| 2021-03-31 | $3.00K 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |